FDG-PET in diagnosis, staging and prognosis of pancreatic carcinoma: A meta-analysis

World Journal of Gastroenterology

Volumn 19, Issue 29, 2013, Pages 4808-4817

  Wang, Zhen ^a   Chen, Jun Qiang ^a   Liu, Jin Lu ^a   Qin, Xin Gan ^a   Huang, Yuan ^a  

^a FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

Diagnosis; Metaanalysis; Pancreatic carcinoma; Positron emission tomography; Prognosis; Staging

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ARTICLE; CANCER PROGNOSIS; CANCER STAGING; DIAGNOSTIC TEST ACCURACY STUDY; HUMAN; META ANALYSIS; PANCREAS CARCINOMA; POSITRON EMISSION TOMOGRAPHY; PUBLISHING; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

EID: 84881054458     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i29.4808     Document Type: Article

References (61)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-249 [PMID: 19474385 DOI: 10.3322/caac.20006]
2. Sharma C, Eltawil KM, Renfrew PD, Walsh MJ, Molinari M. Advances in diagnosis, treatment and palliation of pancreatic carcinoma: 1990-2010. World J Gastroenterol 2011; 17: 867-897 [PMID: 21412497 DOI: 10.3748/wjg.v17.i7.867]
3. Heinrich S, Goerres GW, Schäfer M, Sagmeister M, Bauerfeind P, Pestalozzi BC, Hany TF, von Schulthess GK, Clavien PA. Positron emission tomography/computed tomography influences on the management of resectable pancreatic cancer and its cost-effectiveness. Ann Surg 2005; 242: 235-243 [PMID: 16041214 DOI: 10.1097/01.sla.0000172095.97787.84]
4. American Cancer Society. Pancreatic cancer. Available from: URL: http://www.cancer.org
5. Katz MH, Savides TJ, Moossa AR, Bouvet M. An evidencebased approach to the diagnosis and staging of pancreatic cancer. Pancreatology 2005; 5: 576-590 [PMID: 16110256 DOI: 10.1159/000087500]
6. Wu LM, Hu JN, Hua J, Liu MJ, Chen J, Xu JR. Diagnostic value of diffusion-weighted magnetic resonance imaging compared with fluorodeoxyglucose positron emission tomography/ computed tomography for pancreatic malignancy: a meta-analysis using a hierarchical regression model. J Gastroenterol Hepatol 2012; 27: 1027-1035 [PMID: 22414092 DOI: 10.1111/j.1440-1746.2012.07112.x]
7. Grassetto G, Rubello D. Role of FDG-PET/CT in diagnosis, staging, response to treatment, and prognosis of pancreatic cancer. Am J Clin Oncol 2011; 34: 111-114 [PMID: 21483236 DOI: 10.1097/COC.0b013e3181d275a0]
8. van Kouwen MC, Oyen WJ, Nagengast FM, Jansen JB, Drenth JP. FDG-PET scanning in the diagnosis of gastrointestinal cancers. Scand J Gastroenterol Suppl 2004; (241): 85-92 [PMID: 15696855 DOI: 10.1080/00855920410014614]
9. Mansour JC, Schwartz L, Pandit-Taskar N, D'Angelica M, Fong Y, Larson SM, Brennan MF, Allen PJ. The utility of F-18 fluorodeoxyglucose whole body PET imaging for determining malignancy in cystic lesions of the pancreas. J Gastrointest Surg 2006; 10: 1354-1360 [PMID: 17175454 DOI: 10.1016/j.gassur.2006.08.002]
10. Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol 2003; 3: 25 [PMID: 14606960 DOI: 10.1186/1471-2288-3-25]
11. Hayden JA, Côté P, Bombardier C. Evaluation of the quality of prognosis studies in systematic reviews. Ann Intern Med 2006; 144: 427-437 [PMID: 16549855 DOI: 10.7326/0003-4819 -144-6-200603210-00010]
12. Arends LR, Hamza TH, van Houwelingen JC, Heijenbrok- Kal MH, Hunink MG, Stijnen T. Bivariate random effects meta-analysis of ROC curves. Med Decis Making 2008; 28: 621-638 [PMID: 18591542 DOI: 10.1177/0272989X08319957]
13. Geersing GJ, Janssen KJ, Oudega R, Bax L, Hoes AW, Reitsma JB, Moons KG. Excluding venous thromboembolism using point of care D-dimer tests in outpatients: a diagnostic meta-analysis. BMJ 2009; 339: b2990 [PMID: 19684102 DOI: 10.1136/bmj.b2990]
14. Reitsma JB, Glas AS, Rutjes AW, Scholten RJ, Bossuyt PM, Zwinderman AH. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J Clin Epidemiol 2005; 58: 982-990 [PMID: 16168343 DOI: 10.1016/j.jclinepi.2005.02.022]
15. Deeks JJ, Macaskill P, Irwig L. The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol 2005; 58: 882-893 [PMID: 16085191 DOI: 10.1016/ j.jclinepi.2005.01.016]
16. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998; 17: 2815-2834 [PMID: 9921604]
17. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007; 8: 16 [PMID: 17555582 DOI: 10.1186/1745-6215-8-16]
18. Kauhanen SP, Komar G, Seppänen MP, Dean KI, Minn HR, Kajander SA, Rinta-Kiikka I, Alanen K, Borra RJ, Puolakkainen PA, Nuutila P, Ovaska JT. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer. Ann Surg 2009; 250: 957-963 [PMID: 19687736 DOI: 10.1097/ SLA.0b013e3181b2fafa]
19. Nishiyama Y, Yamamoto Y, Monden T, Sasakawa Y, Tsutsui K, Wakabayashi H, Ohkawa M. Evaluation of delayed additional FDG PET imaging in patients with pancreatic tumour. Nucl Med Commun 2005; 26: 895-901 [PMID: 16160649 DOI: 10.1097/00006231-200510000-00008]
20. Bares R, Klever P, Hauptmann S, Hellwig D, Fass J, Cremerius U, Schumpelick V, Mittermayer C, Büll U. F-18 fluorodeoxyglucose PET in vivo evaluation of pancreatic glucose metabolism for detection of pancreatic cancer. Radiology 1994; 192: 79-86 [PMID: 8208970]
21. Ruf J, Lopez Hänninen E, Böhmig M, Koch I, Denecke T, Plotkin M, Langrehr J, Wiedenmann B, Felix R, Amthauer H. Impact of FDG-PET/MRI image fusion on the detection of pancreatic cancer. Pancreatology 2006; 6: 512-519 [PMID: 17106215 DOI: 10.1159/000096993]
22. Strobel K, Heinrich S, Bhure U, Soyka J, Veit-Haibach P, Pestalozzi BC, Clavien PA, Hany TF. Contrast-enhanced 18FFDG PET/CT: 1-stop-shop imaging for assessing the resectability of pancreatic cancer. J Nucl Med 2008; 49: 1408-1413 [PMID: 18703604 DOI: 10.2967/jnumed.108.051466]
23. Nakamoto Y, Higashi T, Sakahara H, Tamaki N, Kogire M, Imamura M, Konishi J. Contribution of PET in the detection of liver metastases from pancreatic tumours. Clin Radiol 1999; 54: 248-252 [PMID: 10210345 DOI: 10.1016/ S0009-9260(99)91160-1]
24. Nishiyama Y, Yamamoto Y, Yokoe K, Monden T, Sasakawa Y, Tsutsui K, Satoh K, Ohkawa M. Contribution of whole body FDG-PET to the detection of distant metastasis in pancreatic cancer. Ann Nucl Med 2005; 19: 491-497 [PMID: 16248386 DOI: 10.1007/BF02985577]
25. Borbath I, Van Beers BE, Lonneux M, Schoonbroodt D, Geubel A, Gigot JF, Deprez PH. Preoperative assessment of pancreatic tumors using magnetic resonance imaging, endoscopic ultrasonography, positron emission tomography and laparoscopy. Pancreatology 2005; 5: 553-561 [PMID: 16113592 DOI: 10.1159/000087497]
26. Sperti C, Pasquali C, Chierichetti F, Ferronato A, Decet G, Pedrazzoli S. 18-Fluorodeoxyglucose positron emission tomography in predicting survival of patients with pancreatic carcinoma. J Gastrointest Surg 2003; 7: 953-959; discussion 959-960 [PMID: 14675704 DOI: 10.1016/j.gassur.2003.09.002]
27. Maisey NR, Webb A, Flux GD, Padhani A, Cunningham DC, Ott RJ, Norman A. FDG-PET in the prediction of survival of patients with cancer of the pancreas: a pilot study. Br J Cancer 2000; 83: 287-293 [PMID: 10917540 DOI: 10.1054/ bjoc.2000.1166]
28. Zimny M, Fass J, Bares R, Cremerius U, Sabri O, Buechin P, Schumpelick V, Buell U. Fluorodeoxyglucose positron emission tomography and the prognosis of pancreatic carcinoma. Scand J Gastroenterol 2000; 35: 883-888 [PMID: 10994629 DOI: 10.1080/003655200750023273]
29. Nakata B, Nishimura S, Ishikawa T, Ohira M, Nishino H, Kawabe J, Ochi H, Hirakawa K. Prognostic predictive value of 18F-fluorodeoxyglucose positron emission tomography for patients with pancreatic cancer. Int J Oncol 2001; 19: 53-58 [PMID: 11408922]
30. Maemura K, Takao S, Shinchi H, Noma H, Mataki Y, Kurahara H, Jinnouchi S, Aikou T. Role of positron emission tomography in decisions on treatment strategies for pancreatic cancer. J Hepatobiliary Pancreat Surg 2006; 13: 435-441 [PMID: 17013719 DOI: 10.1007/s00534-006-1102-8]
31. Nakata B, Chung YS, Nishimura S, Nishihara T, Sakurai Y, Sawada T, Okamura T, Kawabe J, Ochi H, Sowa M. 18Ffluorodeoxyglucose positron emission tomography and the prognosis of patients with pancreatic adenocarcinoma. Cancer 1997; 79: 695-699 [PMID: 9024707 DOI: 10.1002/(SICI)1097-0142(19970215)79]
32. Stollfuss JC, Glatting G, Friess H, Kocher F, Berger HG, Reske SN. 2-(fluorine-18)-fluoro-2-deoxy-D-glucose PET in detection of pancreatic cancer: value of quantitative image interpretation. Radiology 1995; 195: 339-344 [PMID: 7724750]
33. Wang X, Yu LJ. 18F-FDG PET/CT in detection of pancreatic cancer: Value of synthetic analysis interpretation. Zhongguo Yixue Yingxiang Jishu 2007; 23: 1709-1712
34. Rose DM, Delbeke D, Beauchamp RD, Chapman WC, Sandler MP, Sharp KW, Richards WO, Wright JK, Frexes ME, Pinson CW, Leach SD. 18Fluorodeoxyglucose-positron emission tomography in the management of patients with suspected pancreatic cancer. Ann Surg 1999; 229: 729-737; discussion 737-738 [PMID: 10235532 DOI: 10.1097/00000658 -199905000-00016]
35. Herrmann K, Erkan M, Dobritz M, Schuster T, Siveke JT, Beer AJ, Wester HJ, Schmid RM, Friess H, Schwaiger M, Kleeff J, Buck AK. Comparison of 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography (FLT PET) and FDG PET/CT for the detection and characterization of pancreatic tumours. Eur J Nucl Med Mol Imaging 2012; 39: 846-851 [PMID: 22278320 DOI: 10.1007/s00259-012-2061-8]
36. Nakamoto Y, Higashi T, Sakahara H, Tamaki N, Kogire M, Doi R, Hosotani R, Imamura M, Konishi J. Delayed (18)Ffluoro- 2-deoxy-D-glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas. Cancer 2000; 89: 2547-2554 [PMID: 11135214]
37. Friess H, Langhans J, Ebert M, Beger HG, Stollfuss J, Reske SN, Büchler MW. Diagnosis of pancreatic cancer by 2[18F]- fluoro-2-deoxy-D-glucose positron emission tomography. Gut 1995; 36: 771-777 [PMID: 7797130 DOI: 10.1136/ gut.36.5.771]
38. Keogan MT, Tyler D, Clark L, Branch MS, McDermott VG, DeLong DM, Coleman RE. Diagnosis of pancreatic carcinoma: role of FDG PET. AJR Am J Roentgenol 1998; 171: 1565-1570 [PMID: 9843289 DOI: 10.2214/ajr.171.6.9843289]
39. Koyama K, Okamura T, Kawabe J, Nakata B, Chung KH, Ochi H, Yamada R. Diagnostic usefulness of FDG PET for pancreatic mass lesions. Ann Nucl Med 2001; 15: 217-224 [PMID: 11545191 DOI: 10.1007/BF02987835]
40. Inokuma T, Tamaki N, Torizuka T, Magata Y, Fujii M, Yonekura Y, Kajiyama T, Ohshio G, Imamura M, Konishi J. Evaluation of pancreatic tumors with positron emission tomography and F-18 fluorodeoxyglucose: comparison with CT and US. Radiology 1995; 195: 345-352 [PMID: 7724751]
41. van Kouwen MC, Jansen JB, van Goor H, de Castro S, Oyen WJ, Drenth JP. FDG-PET is able to detect pancreatic carcinoma in chronic pancreatitis. Eur J Nucl Med Mol Imaging 2005; 32: 399-404 [PMID: 15549297 DOI: 10.1007/ s00259-004-1689-4]
42. Zimny M, Bares R, Fass J, Adam G, Cremerius U, Dohmen B, Klever P, Sabri O, Schumpelick V, Buell U. Fluorine-18 fluorodeoxyglucose positron emission tomography in the differential diagnosis of pancreatic carcinoma: a report of 106 cases. Eur J Nucl Med 1997; 24: 678-682 [PMID: 9169578]
43. Kato T, Fukatsu H, Ito K, Tadokoro M, Ota T, Ikeda M, Isomura T, Ito S, Nishino M, Ishigaki T. Fluorodeoxyglucose positron emission tomography in pancreatic cancer: an unsolved problem. Eur J Nucl Med 1995; 22: 32-39 [PMID: 7698152 DOI: 10.1007/BF00997245]
44. Rasmussen I, Sörensen J, Långström B, Haglund U. Is positron emission tomography using 18F-fluorodeoxyglucose and 11C-acetate valuable in diagnosing indeterminate pancreatic masses? Scand J Surg 2004; 93: 191-197 [PMID: 15544073]
45. Delbeke D, Rose DM, Chapman WC, Pinson CW, Wright JK, Beauchamp RD, Shyr Y, Leach SD. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma. J Nucl Med 1999; 40: 1784-1791 [PMID: 10565771]
46. Farma JM, Santillan AA, Melis M, Walters J, Belinc D, Chen DT, Eikman EA, Malafa M. PET/CT fusion scan enhances CT staging in patients with pancreatic neoplasms. Ann Surg Oncol 2008; 15: 2465-2471 [PMID: 18551347 DOI: 10.1245/ s10434-008-9992-0]
47. Sendler A, Avril N, Helmberger H, Stollfuss J, Weber W, Bengel F, Schwaiger M, Roder JD, Siewert JR. Preoperative evaluation of pancreatic masses with positron emission tomography using 18F-fluorodeoxyglucose: diagnostic limitations. World J Surg 2000; 24: 1121-1129 [PMID: 11036292 DOI: 10.1007/s002680010182]
48. Bang S, Chung HW, Park SW, Chung JB, Yun M, Lee JD, Song SY. The clinical usefulness of 18-fluorodeoxyglucose positron emission tomography in the differential diagnosis, staging, and response evaluation after concurrent chemoradiotherapy for pancreatic cancer. J Clin Gastroenterol 2006; 40: 923-929 [PMID: 17063113 DOI: 10.1097/01. mcg.0000225672.68852.05]
49. Papós M, Takács T, Trón L, Farkas G, Ambrus E, Szakáll S, Lonovics J, Csernay L, Pávics L. The possible role of F-18 FDG positron emission tomography in the differential diagnosis of focal pancreatic lesions. Clin Nucl Med 2002; 27: 197-201 [PMID: 11852308 DOI: 10.1097/00003072-200203000-00010]
50. Rajput A, Stellato TA, Faulhaber PF, Vesselle HJ, Miraldi F. The role of fluorodeoxyglucose and positron emission tomography in the evaluation of pancreatic disease. Surgery 1998; 124: 793-797; discussion 793-797 [PMID: 9781003 DOI: 10.1067/msy.1998.91226]
51. Ho CL, Dehdashti F, Griffeth LK, Buse PE, Balfe DM, Siegel BA. FDG-PET evaluation of indeterminate pancreatic masses. J Comput Assist Tomogr 1996; 20: 363-369 [PMID: 8626891 DOI: 10.1097/00004728-199605000-00006]
52. Mertz HR, Sechopoulos P, Delbeke D, Leach SD. EUS, PET, and CT scanning for evaluation of pancreatic adenocarcinoma. Gastrointest Endosc 2000; 52: 367-371 [PMID: 10968852 DOI: 10.1067/mge.2000.107727]
53. Takanami K, Hiraide T, Tsuda M, Nakamura Y, Kaneta T, Takase K, Fukuda H, Takahashi S. Additional value of FDG PET/CT to contrast-enhanced CT in the differentiation between benign and malignant intraductal papillary mucinous neoplasms of the pancreas with mural nodules. Ann Nucl Med 2011; 25: 501-510 [PMID: 21537945 DOI: 10.1007/ s12149-011-0494-y]
54. Sperti C, Bissoli S, Pasquali C, Frison L, Liessi G, Chierichetti F, Pedrazzoli S. 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas. Ann Surg 2007; 246: 932-937; discussion 937-939 [PMID: 18043094 DOI: 10.1097/SLA.0b013e31815c2a29]
55. Tann M, Sandrasegaran K, Jennings SG, Skandarajah A, McHenry L, Schmidt CM. Positron-emission tomography and computed tomography of cystic pancreatic masses. Clin Radiol 2007; 62: 745-751 [PMID: 17604762 DOI: 10.1016/ j.crad.2007.01.023]
56. Bares R, Klever P, Hellwig D, Hauptmann S, Fass J, Hambuechen U, Zopp L, Mueller B, Buell U, Schumpelick V. Pancreatic cancer detected by positron emission tomography with 18F-labelled deoxyglucose: method and first results. Nucl Med Commun 1993; 14: 596-601 [PMID: 8355920 DOI: 10.1097/00006231-199307000-00013]
57. Howes N, Lerch MM, Greenhalf W, Stocken DD, Ellis I, Simon P, Truninger K, Ammann R, Cavallini G, Charnley RM, Uomo G, Delhaye M, Spicak J, Drumm B, Jansen J, Mountford R, Whitcomb DC, Neoptolemos JP. Clinical and genetic characteristics of hereditary pancreatitis in Europe. Clin Gastroenterol Hepatol 2004; 2: 252-261 [PMID: 15017610 DOI: 10.1016/S1542-3565(04)00013-8]
58. Asagi A, Ohta K, Nasu J, Tanada M, Nadano S, Nishimura R, Teramoto N, Yamamoto K, Inoue T, Iguchi H. Utility of contrast-enhanced FDG-PET/CT in the clinical management of pancreatic cancer: impact on diagnosis, staging, evaluation of treatment response, and detection of recurrence. Pancreas 2013; 42: 11-19 [PMID: 22699206 DOI: 10.1097/ MPA.0b013e3182550d77]
59. Quon A, Chang ST, Chin F, Kamaya A, Dick DW, Loo BW, Gambhir SS, Koong AC. Initial evaluation of 18F-fluorothymidine (FLT) PET/CT scanning for primary pancreatic cancer. Eur J Nucl Med Mol Imaging 2008; 35: 527-531 [PMID: 17960376 DOI: 10.1007/s00259-007-0630-z]
60. Lyshchik A, Higashi T, Nakamoto Y, Fujimoto K, Doi R, Imamura M, Saga T. Dual-phase 18F-fluoro-2-deoxy-Dglucose positron emission tomography as a prognostic parameter in patients with pancreatic cancer. Eur J Nucl Med Mol Imaging 2005; 32: 389-397 [PMID: 15372209 DOI: 10.1007/s00259-004-1656-0]
61. Topkan E, Parlak C, Kotek A, Yapar AF, Pehlivan B. Predictive value of metabolic 18FDG-PET response on outcomes in patients with locally advanced pancreatic carcinoma treated with definitive concurrent chemoradiotherapy. BMC Gastroenterol 2011; 11: 123 [PMID: 22074002 DOI: 10.1186/14 71-230X-11-123]